At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions. Diabetes poses one of todayÍs biggest global health challenges. We work for a future where fewer people get diabetes, everyone with diabetes is diagnosed, and everyone who is diagnosed receives adequate treatment and can live a life with as few limitations as possible.
Since the company was founded in Denmark more than 90 years ago, we have been changing diabetes. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Our ambition is to take the lead in each of these areas, driving change with an unfailing belief that it can be done.
This page isnÍt intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.
Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo NordiskÍs office in the country you live in: http://novonordisk.com/about_us/global_offices/global_offices.asp.
For other customer complaints please contact us here: http://novonordisk.com/about_us/contact_us/contact_us.asp
Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industries. Therefore, comments that pertain to legal matters or regulatory issues may be removed.
Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other Linkedin users.
Learn more about our community guidelines here http://bit.ly/NN-disclaimer
- Company Name:Novo Nordisk
(View Trends)
-
Headquarters: (View Map)Bagsvaerd, Denmark
-
Pharmaceuticals
-
> 10,000 employees
- 168503 Global Rank
- 3882 Denmark
- 292 K Estimated Visits
-
Direct36.50%
-
Search32.96%
-
Social21.07%
-
Referrals8.45%
-
Mail1.00%
-
Display0.02%
-
36.63%
-
11.53%
-
8.66%
-
4.59%
- India 25.1%
- Saudi Arabia 17.2%
- Denmark 14.7%
- United States 5.5%
- Sweden 3.5%
- Biotechnology and Pharmaceuticals
- Pharmaceuticals
- 1 K Downloads
- 1 SDKs
- 3.0 Avg. Rating
- 4 Total reviews
- App Url: https://play.google.com/store/apps/details?id=com.novo.app.coags
- App Support: http://www.novonordisk-us.com/
- Genre: medical
- Bundle ID: com.novo.app.coags
- App Size: 3.72 M
- Version: 300008
- Release Date: December 7th, 2012
- Update Date: November 15th, 2016
Description:
Simplified testing and diagnosis of coagulation disorders
Coags Uncomplicated is a diagnostic tool for coagulation disorders developed by Novo Nordisk in partnership with: Craig M. Kessler, MD, MACP, Professor of Medicine and Pathology, Director of the Coagulation Laboratory, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC; Ellinor I. Peerschke, PhD, FAHA, Vice Chair, Department of Laboratory Medicine, Head of Hematology and Coagulation Laboratory Services, Memorial Sloan-Kettering Cancer Center, New York, NY; Meera B. Chitlur, MD, Associate Professor of Pediatrics, Wayne State University School of Medicine, Staff Physician, Division of Hematology/Oncology, Children’s Hospital of Michigan, Detroit, MI; and Roshni Kulkarni, MD, Professor of Pediatrics and Human Development, Director of Pediatric and Adolescent Hematology/Oncology, College of Human Medicine, Michigan State University, East Lansing, MI.
Coags Uncomplicated provides valuable tools to aid you in the diagnosis of bleeding disorders and interpretation of coagulation lab tests. Now this app has been enhanced to help expand your ability to begin diagnosing on the go. Existing features and new enhancements include:
• Lab Value Analyzer: Enter your patient’s lab results and receive a list of suggested diagnoses, including bleeding disorders with abnormal prothrombin time (PT) and/or activated partial thromboplastin time (aPTT) and with normal PT/aPTT
• Diagnostic Algorithm: Start with PT and aPTT results, and then go step by step to narrow possible diagnoses, including platelet disorders
• Neonatal Module: Receive specialized assistance to help you diagnose bleeding disorders in the neonatal population where normal values are age sensitive
• Face a Case: Test your clinical skills with 5 case studies across a variety of bleeding disorders, both adult and pediatric
• Coag Challenge: Answer challenging bleeding disorder questions in an educational, fast-paced quiz
Coags Uncomplicated was developed as a guide. Clinical correlation and consultation with a hematologist are advised to ensure an accurate diagnosis.
Download this free app now to turn the complex coagulation cascade into an easy-to-use diagnostic resource!
Novo Nordisk Inc., 100 College Road West, Princeton, New Jersey 08540 U.S.A.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Coags UncomplicatedTM is a trademark of Novo Nordisk Health Care AG.
© 2012 Novo Nordisk All rights reserved. 0912-00011357-1 December 2012
-
Standard93.65%
-
Direct6.35%
They are headquartered at Bagsvaerd, Denmark, and have 39 advertising & marketing contacts listed on Kochava. Novo Nordisk works with Advertising technology companies such as Videology, The Trade Desk, Chango, Dstillery, Turn, Neustar AdAdvisor, AOL-Time Warner Online Advertising, Media Innovation Group, Atlas, DoubleClick.Net, AppNexus, BlueKai, Resonate Insights, DemDex, Facebook Exchange FBX, AppNexus Segment Pixel, Yahoo Small Business, Facebook Custom Audiences, LinkedIn Ads, Bizo, Google Remarketing, Twitter Ads, DoubleClick Bid Manager, Adobe Audience Manager.
